STAT5A

Summary

STAT5A (signal transducer and activator of transcription 5A, HGNC:11366) is a protein-coding gene on chromosome 17q21.2, encoding Signal transducer and activator of transcription 5A (P42229). Carries out a dual function: signal transduction and activation of transcription.

The protein encoded by this gene is a member of the STAT family of transcription factors. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein is activated by, and mediates the responses of many cell ligands, such as IL2, IL3, IL7 GM-CSF, erythropoietin, thrombopoietin, and different growth hormones. Activation of this protein in myeloma and lymphoma associated with a TEL/JAK2 gene fusion is independent of cell stimulus and has been shown to be essential for tumorigenesis. The mouse counterpart of this gene is found to induce the expression of BCL2L1/BCL-X(L), which suggests the antiapoptotic function of this gene in cells. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 6776 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 90 total
• Phenotypes (HPO): 2
• Druggable target: yes — 4 molecules with ChEMBL bioactivity
• Transcription factor: yes — 229 downstream targets (CollecTRI)
• MANE Select transcript: NM_001288718

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11366
Approved symbol	STAT5A
Name	signal transducer and activator of transcription 5A
Location	17q21.2
Locus type	gene with protein product
Status	Approved
Aliases	MGF
Ensembl gene	ENSG00000126561
Ensembl biotype	protein_coding
OMIM	601511
Entrez	6776

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 22 protein_coding, 5 retained_intron

ENST00000345506, ENST00000468096, ENST00000469124, ENST00000479417, ENST00000546010, ENST00000587646, ENST00000588868, ENST00000590726, ENST00000590949, ENST00000591556, ENST00000676585, ENST00000676631, ENST00000677301, ENST00000677893, ENST00000678903, ENST00000879661, ENST00000879662, ENST00000946350, ENST00000946351, ENST00000946352, ENST00000946353, ENST00000946354, ENST00000946355, ENST00000946356, ENST00000946357, ENST00000946358, ENST00000946359

RefSeq mRNA: 5 — MANE Select: NM_001288718 NM_001288718, NM_001288719, NM_001288720, NM_001411103, NM_003152

CCDS: CCDS11424, CCDS74066, CCDS74067, CCDS92308

Canonical transcript exons

ENST00000590949 — 19 exons

Exon	Start	End
ENSE00000865290	42304342	42304429
ENSE00001319829	42310507	42311943
ENSE00002328222	42306241	42306447
ENSE00002342990	42301275	42301454
ENSE00002404780	42300715	42300870
ENSE00002414164	42299751	42299881
ENSE00002919630	42288498	42288598
ENSE00003542285	42304530	42304652
ENSE00003571676	42307593	42307723
ENSE00003582163	42295619	42295793
ENSE00003612410	42309377	42309484
ENSE00003617816	42309047	42309098
ENSE00003638145	42305610	42305702
ENSE00003648388	42289402	42289539
ENSE00003653620	42308178	42308333
ENSE00003659005	42289866	42290022
ENSE00003691789	42307402	42307496
ENSE00003785264	42300130	42300281
ENSE00003786074	42291972	42292061

Expression profiles

Bgee: expression breadth ubiquitous, 190 present calls, max score 95.66.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 26.7264 / max 514.5823, expressed in 1585 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
160931	14.2795	1527
160933	5.7423	174
160927	1.8049	283
160930	1.5424	291
160926	1.5339	461
160925	0.7425	172
160932	0.3649	93
160929	0.2968	109
160935	0.1820	73
160928	0.1070	58

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	95.66	gold quality
monocyte	CL:0000576	94.20	gold quality
leukocyte	CL:0000738	93.99	gold quality
left adrenal gland cortex	UBERON:0035825	93.99	gold quality
right adrenal gland cortex	UBERON:0035827	93.96	gold quality
left adrenal gland	UBERON:0001234	93.89	gold quality
mononuclear cell	CL:0000842	93.88	gold quality
right adrenal gland	UBERON:0001233	93.86	gold quality
subcutaneous adipose tissue	UBERON:0002190	93.48	gold quality
tendon of biceps brachii	UBERON:0008188	93.28	gold quality
omental fat pad	UBERON:0010414	93.03	gold quality
peritoneum	UBERON:0002358	92.96	gold quality
adipose tissue of abdominal region	UBERON:0007808	92.70	gold quality
adipose tissue	UBERON:0001013	92.23	gold quality
connective tissue	UBERON:0002384	91.68	gold quality
adrenal cortex	UBERON:0001235	91.64	gold quality
blood	UBERON:0000178	91.50	gold quality
adrenal gland	UBERON:0002369	91.23	gold quality
mucosa of stomach	UBERON:0001199	90.84	gold quality
vermiform appendix	UBERON:0001154	90.31	gold quality
lymph node	UBERON:0000029	90.11	gold quality
muscle layer of sigmoid colon	UBERON:0035805	89.82	gold quality
spleen	UBERON:0002106	89.52	gold quality
right ovary	UBERON:0002118	89.41	gold quality
left uterine tube	UBERON:0001303	89.40	gold quality
right coronary artery	UBERON:0001625	89.40	gold quality
tibial nerve	UBERON:0001323	89.39	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	89.35	gold quality
left coronary artery	UBERON:0001626	89.26	gold quality
upper lobe of left lung	UBERON:0008952	89.07	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-9067	yes	21.76
E-CURD-112	yes	8.45
E-ANND-3	yes	8.37

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

229 targets.

Target	Regulation
A2M
ABCB1
ABL1
ACACA
ACO1	Unknown
ACOX1
ADAM2
AKT1
ALK
ANP32A	Activation
AR
AURKA	Unknown
BCL10
BCL2	Unknown
BCL2L1	Unknown
BCL2L11
BCL6	Repression
BCR
BMX
C4A
C4B
CALCA
CAT
CCL1	Unknown
CCL2	Activation
CCL8	Activation
CCND1	Unknown
CCND2	Repression
CCND3	Activation
CD207

Upstream regulators (CollecTRI, top): AR, BCL6, CREB1, CUX1, ELF5, ESR1, ESR2, FOXO3, ID1, MAX, NFATC2, NFIB, NFIC, NFKB1, NFKB, PGR, PPARA, PPARG, RELA, STAT3, STAT5A, STAT5B

miRNA regulators (miRDB)

39 targeting STAT5A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-8084	99.73	69.57	1760
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-4663	99.62	65.33	957
HSA-MIR-6758-3P	99.57	67.55	1078
HSA-MIR-141-5P	99.57	67.86	897
HSA-MIR-4672	99.50	71.58	2893
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-6088	99.29	68.45	1284
HSA-MIR-548L	99.06	70.90	2560
HSA-MIR-6761-5P	98.71	68.03	1504
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-210-5P	98.57	64.37	832

Literature-anchored findings (GeneRIF, showing 40)

• Jak-Stat and PI 3-kinase activation pathways regulate the TPO-induced survival of megakaryocytic cells via Bcl-xL gene expression. (PMID:11756417)
• To examine the roles of BCR/ABL-activated individual signaling molecules we inducibly expressed a dominant negative (DN) form of Ras, phosphatidylinositol 3-kinase, and STAT5 alone or in combination in p210 BCR/ABL-positive K562 cells. (PMID:11779872)
• substrates for calpain in in platelets[stat5protease] (PMID:11861304)
• STAT5 isoform expression, GM-CSF-induced STAT5 activation, and STAT5 target-gene expression are altered significantly during monocyte/macrophage differentiation (PMID:11867689)
• increase in Cyclin D1 promoter activity is predominantly mediated by the Jak2/Stat5 signaling pathway. PRL induces Stat5a and 5b to bind to Cyclin D1 promoter (PMID:11923474)
• constitutive activation of Stat5a may contribute to head and neck cancer cell proliferation. (PMID:11973644)
• Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB. (PMID:12091337)
• CPAP was found to augment Stat5-mediated transcription (PMID:12198240)
• NF-kappaB is recruited directly to the promoters of several target genes, including STAT5a (PMID:12208876)
• Signal transducer and activator of transcription (Stat)5a and Stat5b are critical for normal immune function. (PMID:12377952)
• role during eosinophil differentiation using umbilical cord blood-derived CD34(+) cells (PMID:12393707)
• Role of c-Jun-N-terminal kinase and signal transducer and activator of transcription 5 in regulation of eosinophil apoptosis by nitric oxide. (PMID:12847485)
• Stat5 plays an important role in IFN-signaling and participates in the induction of Type I IFN-dependent responses. (PMID:12901872)
• STAT5, in concert with the glucocorticoid receptor, recruits a multifunctional coactivator complex to initiate the PRL-dependent transcription (PMID:12954634)
• Stat5-mediated gene transcription requires binding of the coactivator of transcription CBP (PMID:14597631)
• We show that the association of STAT5 and LMW-PTP does not exclusively involve the phosphatase active site and phosphotyrosine residue of STAT5. (PMID:14637146)
• Stat5a was nuclear localized and tyrosine phosphorylated in 59 of 78 (76%) breast cancers examined; 38 of 78 (49%) demonstrated Stat5a nuclear localization in more than 25% of the breast cancer cells within the adenocarcinomas. (PMID:14696092)
• In advanced arteriosclerotic lesions, the activation of the Tie2-mediated STAT5 signaling pathway may negatively regulate vessel growth. (PMID:14726409)
• diminished N-domain-mediated oligomerization affected transcriptional activation by both Stat1 and Stat5a/b in a promoter-specific manner. (PMID:15010467)
• IL-7 induced the death of DN STAT5 expressing 697 cells occurs through caspase-dependent and -independent mechanisms that both require mitochondrial activation. (PMID:15048088)
• Perturbation of STAT5a&b expression by addition of ODNs decreased proliferative potential of the CML and the AML blasts as well as enhanced their apoptosis (PMID:15128421)
• Stat5 activity in human breast cancer correlates with favorable prognosis (PMID:15169792)
• Aberrant regulation of STAT5 has been observed in solid tumors as well as in patients with either chronic or acute myeloid leukemia [review]. (PMID:15313458)
• STAT5A has a role in human hematopoietic stem and progenitor cell self-renewal and diverts differentiation to the erythroid lineage (PMID:15353555)
• STAT5 is involved in cytokine-mediated up-regulation of MIST gene expression. (PMID:15358227)
• nuclear localization of STAT5A and stimulation of the beta-casein promoter requires nuclear translocation of the ERBB4 intracellular domain 4ICD; binding of the two proteins at transcription factor target promoters results in activation of gene expression (PMID:15534001)
• an invasion-suppressive role of Stat5 in human breast cancer (PMID:15592524)
• STAP-2/BKS is a modulator of STAT5-mediated signaling (PMID:15611091)
• These data suggest that Stat5 tetramers are associated with leukemogenesis. (PMID:15652752)
• Results indicate that SOCS-7 is a dysregulator of prolactin, leptin, and growth hormone signaling and that its mode of action is a variation of SOCS protein inhibition of cytokine-inducible STAT3 and 5-mediated signal transduction. (PMID:15677474)
• Consistently, overexpression of a constitutive active STAT5A leads to anchorage-independent cell cycle progression. Therefore, integrin-dependent STAT5A activation controls IL-3-mediated proliferation. (PMID:15795318)
• Study shows that active Stat5 distinguished prostate cancer patients whose disease is likely to progress earlier; therefore, active Stat5 may be a useful marker for selection of more individualized treatment. (PMID:16115927)
• The absence of STAT 5a in the abnormal breast epithelial cells may indicate a defect contributory to the abnormal state. (PMID:16133357)
• Constitutive activation of Stat5A is associated with oral squamous cell carcinoma (PMID:16303247)
• Results suggest that the antiapoptotic effects of erythropoietin in neuronal cells require the combinatorial activation of multiple signaling pathways, including STAT5, AKT, and potentially MAP kinase. (PMID:16407271)
• down-modulation of C/EBPalpha is a prerequisite for STAT5-induced effects on self-renewal and myelopoiesis in human cord blood-derived stem/progenitor cells (PMID:16455947)
• STAT5A and STAT5B may play significant roles in the growth and the process of apoptosis of selected human cutaneous T-cell lymphoma cells. (PMID:16502315)
• STAT5 activation specifically cooperates with the loss of p53 function in B-cell lymphomagenesis (PMID:16532027)
• Effect of signal transducer and activator of transcription 5 proteins on indomethacin-induced cell division inhibition in chronic myelogenous leukemia cells. (PMID:16572323)
• In polycythemia vera JAK2(V617F) may induce endogenous erythroid colonies via the STAT5/Bcl-xL pathway. (PMID:16684963)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	stat5a	ENSDARG00000019392
danio_rerio	stat5b	ENSDARG00000055588
mus_musculus	Stat5a	ENSMUSG00000004043
rattus_norvegicus	Stat5a	ENSRNOG00000019496
drosophila_melanogaster	Stat92E	FBGN0016917

Paralogs (6): STAT1 (ENSG00000115415), STAT4 (ENSG00000138378), STAT6 (ENSG00000166888), STAT3 (ENSG00000168610), STAT2 (ENSG00000170581), STAT5B (ENSG00000173757)

Protein

Protein identifiers

Signal transducer and activator of transcription 5A — P42229 (reviewed: P42229)

All UniProt accessions (7): P42229, A0A384N5W4, A0A7I2V380, A0A7I2YQF1, A0A7I2YQY3, K7EIF9, K7EK35

UniProt curated annotations — full annotation on UniProt →

Function. Carries out a dual function: signal transduction and activation of transcription. Mediates cellular responses to the cytokine KITLG/SCF and other growth factors. Mediates cellular responses to ERBB4. May mediate cellular responses to activated FGFR1, FGFR2, FGFR3 and FGFR4. Binds to the GAS element and activates PRL-induced transcription. Regulates the expression of milk proteins during lactation.

Subunit / interactions. Forms a homodimer or a heterodimer with a related family member. Binds NR3C1. Interacts with NCOA1 and SOCS7. Interacts with ERBB4. Interacts with EBF4. Interacts with CD69.

Subcellular location. Cytoplasm. Nucleus.

Post-translational modifications. Tyrosine phosphorylated in response to KITLG/SCF, IL2, IL3, IL7, IL15, CSF2/GMCSF, GH1, PRL, EPO and THPO. Activated KIT promotes phosphorylation on tyrosine residues and subsequent translocation to the nucleus. Tyrosine phosphorylated in response to constitutively activated FGFR1, FGFR2, FGFR3 and FGFR4. Tyrosine phosphorylation is required for DNA-binding activity and dimerization. Serine phosphorylation is also required for maximal transcriptional activity. Tyrosine phosphorylated in response to signaling via activated FLT3; wild-type FLT3 results in much weaker phosphorylation than constitutively activated mutant FLT3. Alternatively, can be phosphorylated by JAK2 at Tyr-694. ISGylated.

Similarity. Belongs to the transcription factor STAT family.

Isoforms (2)

UniProt ID	Names	Canonical?
P42229-1	1	yes
P42229-2	2

RefSeq proteins (5): NP_001275647, NP_001275648, NP_001275649, NP_001398032, NP_003143 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000980	SH2	Domain
IPR001217	STAT	Family
IPR008967	p53-like_TF_DNA-bd_sf	Homologous_superfamily
IPR012345	STAT_TF_DNA-bd_N	Homologous_superfamily
IPR013799	STAT_TF_prot_interaction	Domain
IPR013800	STAT_TF_alpha	Domain
IPR013801	STAT_TF_DNA-bd	Domain
IPR015988	STAT_TF_CC	Homologous_superfamily
IPR035858	STAT5a/5b_DBD	Domain
IPR036535	STAT_N_sf	Homologous_superfamily
IPR036860	SH2_dom_sf	Homologous_superfamily
IPR046994	STAT5_CC	Domain
IPR048988	STAT_linker	Domain

Pfam: PF00017, PF01017, PF02864, PF02865, PF21354

UniProt features (58 total): helix 21, strand 19, turn 6, modified residue 6, chain 1, domain 1, sequence variant 1, sequence conflict 1, region of interest 1, splice variant 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
7UBT	X-RAY DIFFRACTION	2.35
7TVB	X-RAY DIFFRACTION	2.65
7TVA	X-RAY DIFFRACTION	2.83
7UC6	X-RAY DIFFRACTION	3.1
7UC7	X-RAY DIFFRACTION	3.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P42229-F1	85.78	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 90, 128, 193, 682, 694, 780

Function

Pathways and Gene Ontology

Reactome pathways

43 pathways

ID	Pathway
R-HSA-1170546	Prolactin receptor signaling
R-HSA-1251985	Nuclear signaling by ERBB4
R-HSA-1266695	Interleukin-7 signaling
R-HSA-1433557	Signaling by SCF-KIT
R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants
R-HSA-186763	Downstream signal transduction
R-HSA-2586552	Signaling by Leptin
R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling
R-HSA-8854691	Interleukin-20 family signaling
R-HSA-8983432	Interleukin-15 signaling
R-HSA-8985947	Interleukin-9 signaling
R-HSA-9020558	Interleukin-2 signaling
R-HSA-9020958	Interleukin-21 signaling
R-HSA-9027283	Erythropoietin activates STAT5
R-HSA-9645135	STAT5 Activation
R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
R-HSA-9674555	Signaling by CSF3 (G-CSF)
R-HSA-9702518	STAT5 activation downstream of FLT3 ITD mutants
R-HSA-9703465	Signaling by FLT3 fusion proteins
R-HSA-9705462	Inactivation of CSF3 (G-CSF) signaling
R-HSA-9725371	Nuclear events stimulated by ALK signaling in cancer
R-HSA-982772	Growth hormone receptor signaling
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)
R-HSA-1226099	Signaling by FGFR in disease
R-HSA-1236394	Signaling by ERBB4
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-168256	Immune System
R-HSA-1839124	FGFR1 mutant receptor activation

MSigDB gene sets: 668 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GSE45365_NK_CELL_VS_CD11B_DC_DN, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_REGULATION_OF_CELL_ACTIVATION, REACTOME_INTERLEUKIN_2_FAMILY_SIGNALING, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_NATURAL_KILLER_CELL_DIFFERENTIATION, MYOGENIN_Q6, GOBP_GLAND_MORPHOGENESIS, GOBP_NEGATIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_REGULATION_OF_ALPHA_BETA_T_CELL_ACTIVATION, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS

GO Biological Process (76): mitotic cell cycle (GO:0000278), luteinization (GO:0001553), natural killer cell differentiation (GO:0001779), positive regulation of endothelial cell proliferation (GO:0001938), regulation of transcription by RNA polymerase II (GO:0006357), transcription by RNA polymerase II (GO:0006366), defense response (GO:0006952), cell surface receptor signaling pathway via JAK-STAT (GO:0007259), female pregnancy (GO:0007565), lactation (GO:0007595), regulation of steroid metabolic process (GO:0019218), cytokine-mediated signaling pathway (GO:0019221), taurine metabolic process (GO:0019530), lipid storage (GO:0019915), B cell differentiation (GO:0030183), erythrocyte differentiation (GO:0030218), eosinophil differentiation (GO:0030222), regulation of epithelial cell differentiation (GO:0030856), positive regulation of interleukin-2 production (GO:0032743), positive regulation of natural killer cell differentiation (GO:0032825), mast cell apoptotic process (GO:0033024), negative regulation of mast cell apoptotic process (GO:0033026), T cell differentiation in thymus (GO:0033077), interleukin-15-mediated signaling pathway (GO:0035723), interleukin-4-mediated signaling pathway (GO:0035771), reelin-mediated signaling pathway (GO:0038026), interleukin-5-mediated signaling pathway (GO:0038043), interleukin-2-mediated signaling pathway (GO:0038110), interleukin-7-mediated signaling pathway (GO:0038111), interleukin-9-mediated signaling pathway (GO:0038113), interleukin-3-mediated signaling pathway (GO:0038156), thrombopoietin-mediated signaling pathway (GO:0038163), regulation of multicellular organism growth (GO:0040014), positive regulation of multicellular organism growth (GO:0040018), positive regulation of activated T cell proliferation (GO:0042104), regulation of cell population proliferation (GO:0042127), natural killer cell mediated cytotoxicity (GO:0042267), gamma-delta T cell differentiation (GO:0042492), T cell homeostasis (GO:0043029), response to peptide hormone (GO:0043434)

GO Molecular Function (10): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA-binding transcription factor activity (GO:0003700), phosphate ion binding (GO:0042301), DNA-binding transcription factor binding (GO:0140297), promoter-specific chromatin binding (GO:1990841), DNA binding (GO:0003677), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (6): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), RNA polymerase II transcription regulator complex (GO:0090575)

Reactome top-level categories

Rollup of top-14 pathways:

Category	Pathways
Interleukin-2 family signaling	4
Signaling by Interleukins	3
Cytokine Signaling in Immune system	2
Signaling by ERBB4	1
Signaling by Receptor Tyrosine Kinases	1
FGFR1 mutant receptor activation	1
Signaling by PDGF	1
Signal Transduction	1
Signaling by Erythropoietin	1
FLT3 Signaling	1
Signaling by KIT in disease	1
Signaling by FLT3 ITD and TKD mutants	1
FLT3 signaling in disease	1
Signaling by CSF3 (G-CSF)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
lymphocyte differentiation	2
regulation of DNA-templated transcription	2
cell cycle	1
mitotic nuclear division	1
female gonad development	1
ovulation cycle process	1
natural killer cell activation	1
endothelial cell proliferation	1
regulation of endothelial cell proliferation	1
positive regulation of epithelial cell proliferation	1
transcription by RNA polymerase II	1
DNA-templated transcription	1
response to stress	1
cell surface receptor signaling pathway via STAT	1
multi-organism reproductive process	1
multi-multicellular organism process	1
body fluid secretion	1
mammary gland development	1
milk ejection reflex	1
steroid metabolic process	1
regulation of lipid metabolic process	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
alkanesulfonate metabolic process	1
nutrient storage	1
B cell activation	1
myeloid cell differentiation	1
erythrocyte homeostasis	1
granulocyte differentiation	1
cell development	1
epithelial cell differentiation	1
regulation of cell differentiation	1
regulation of multicellular organismal development	1
positive regulation of cytokine production	1
interleukin-2 production	1
regulation of interleukin-2 production	1
natural killer cell differentiation	1
positive regulation of natural killer cell activation	1

Protein interactions and networks

STRING

3898 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STAT5A	JAK2	O60674	997
STAT5A	JAK1	P23458	986
STAT5A	CRKL	P46109	976
STAT5A	STAT3	P40763	974
STAT5A	JAK3	P52333	972
STAT5A	EPOR	P19235	950
STAT5A	EGFR	P00533	933
STAT5A	TYK2	P29597	931
STAT5A	IL7	P13232	930
STAT5A	IL2	P01585	916
STAT5A	CREBBP	Q92793	910
STAT5A	EZH2	Q15910	896
STAT5A	ERBB4	Q15303	893
STAT5A	IL2RA	P01589	887
STAT5A	CSF2	P04141	878

IntAct

91 interactions, top by confidence:

A	B	Type	Score
STAT5A	PDHA1	psi-mi:“MI:0914”(association)	0.640
EGFR	STAT5A	psi-mi:“MI:0915”(physical association)	0.630
STAT5A	TCF12	psi-mi:“MI:0915”(physical association)	0.560
TCF12	STAT5A	psi-mi:“MI:0915”(physical association)	0.560
STAT5A	STAP2	psi-mi:“MI:0915”(physical association)	0.560
STAP2	STAT5A	psi-mi:“MI:0915”(physical association)	0.560
STAP2	STAT5A	psi-mi:“MI:0403”(colocalization)	0.560
STAT5A	AGAP2	psi-mi:“MI:0915”(physical association)	0.560
STAT5A	AGAP2	psi-mi:“MI:0403”(colocalization)	0.560
CSF2RB	JAK2	psi-mi:“MI:0914”(association)	0.560
PTPN1	STAT5A	psi-mi:“MI:0203”(dephosphorylation reaction)	0.560
PTPN1	STAT5A	psi-mi:“MI:0407”(direct interaction)	0.560
STAT5A	MRPS6	psi-mi:“MI:0915”(physical association)	0.550
MRPS6	STAT5A	psi-mi:“MI:0914”(association)	0.550
DDX20	GAPDHS	psi-mi:“MI:0914”(association)	0.530
SF3A1	DNAJC8	psi-mi:“MI:0914”(association)	0.530

BioGRID (164): TCF12 (Two-hybrid), STAT5A (Affinity Capture-Western), PPARG (Affinity Capture-Western), PPARG (Affinity Capture-Western), STAT5A (Affinity Capture-Western), STAT5A (Affinity Capture-Western), STAT5A (Two-hybrid), NLK (Co-localization), NARF (Co-localization), STAT5A (Co-localization), STAT5A (Two-hybrid), PRTFDC1 (Two-hybrid), OLIG1 (Two-hybrid), CBL (Two-hybrid), ADD3 (Affinity Capture-MS)

ESM2 similar proteins: A2A690, A2AWA9, A2RSQ0, A6QL63, F1LTE0, G3V7Q0, O60941, O70585, P40763, P42224, P42227, P42229, P42230, P42231, P52631, P52632, P84060, Q148V7, Q4V8I4, Q5R372, Q5R8N4, Q5RCW6, Q5ZJ17, Q62771, Q62784, Q6DFZ1, Q6DV79, Q6GQW0, Q6IQ26, Q6PAL8, Q6ZPY2, Q6ZUT9, Q7Z3J2, Q8BIK4, Q8CIQ7, Q8IZD9, Q8N122, Q8NFG4, Q92538, Q95115

Diamond homologs: O02799, P40763, P42224, P42225, P42227, P42228, P42229, P42230, P42231, P42232, P51692, P52630, P52631, P52632, P61635, Q14765, Q19S50, Q62771, Q6DV79, Q764M5, Q7ZXK3, Q95115, Q9PVX8, Q9TUM3, Q9TUZ0, Q9TUZ1, Q9WVL2, B5X561, Q24151, Q54BD4, O00910, P42226, P52633, Q61AP6, Q7QDU4, Q70GP4, Q9NAD6

SIGNOR signaling

62 interactions.

A	Effect	B	Mechanism
NCOA1	up-regulates	STAT5A	binding
SRC	up-regulates	STAT5A	phosphorylation
PTPN2	“down-regulates activity”	STAT5A	dephosphorylation
IL3RA	up-regulates	STAT5A
EGFR	up-regulates	STAT5A	binding
ERBB4	up-regulates	STAT5A	binding
JAK3	up-regulates	STAT5A	phosphorylation
PTEN	down-regulates	STAT5A	dephosphorylation
STAT5A	up-regulates	Adipogenesis	“transcriptional regulation”
JAK2	“up-regulates activity”	STAT5A	phosphorylation
STAT5A	“up-regulates quantity by expression”	IRF5	“transcriptional regulation”
STAT5A	up-regulates	M1_polarization
STAT5A	“up-regulates quantity by expression”	PIM1	“transcriptional regulation”
STAT5A	“up-regulates quantity by expression”	IGF1	“transcriptional regulation”
STAT5A	“down-regulates quantity by repression”	MEF2C	“transcriptional regulation”
IL4R	up-regulates	STAT5A
STAT5A	up-regulates	FOXP3
STAT5A	up-regulates	Proliferation
STAT5A	up-regulates	Survival
STAT5A	“up-regulates quantity”	DNMT3A	“transcriptional regulation”
STAT5A	“up-regulates quantity by expression”	PIM	“transcriptional regulation”
STAT5A	“up-regulates quantity by expression”	miR-155	“transcriptional regulation”
STAT5A	up-regulates	Erythrocyte_differentiation
STAT5A	down-regulates	Apoptosis
STAT5A	down-regulates	Cell_death
ponatinib	“down-regulates activity”	STAT5A	“chemical inhibition”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 71 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Growth hormone receptor signaling	5	40.3×	9e-05
Extra-nuclear estrogen signaling	6	17.3×	4e-04
SARS-CoV-2-host interactions	5	10.1×	5e-03
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	5	8.2×	7e-03
Diseases of signal transduction by growth factor receptors and second messengers	8	7.7×	1e-03
SARS-CoV-2 activates/modulates innate and adaptive immune responses	5	7.6×	9e-03
RAF/MAP kinase cascade	7	7.2×	2e-03
Signaling by Interleukins	6	6.5×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
cell surface receptor signaling pathway via JAK-STAT	5	23.4×	7e-04
epidermal growth factor receptor signaling pathway	5	20.0×	1e-03
cytokine-mediated signaling pathway	5	10.5×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

90 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	67
Likely benign	3
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

3887 predictions. Top by Δscore:

Variant	Effect	Δscore
17:42288727:G:GT	donor_gain	1.0000
17:42292060:AT:A	donor_gain	1.0000
17:42292060:ATGTG:A	donor_loss	1.0000
17:42292061:TG:T	donor_loss	1.0000
17:42292062:G:GA	donor_loss	1.0000
17:42292062:G:GG	donor_gain	1.0000
17:42292063:TGAG:T	donor_loss	1.0000
17:42292064:G:GG	donor_loss	1.0000
17:42295617:A:AG	acceptor_gain	1.0000
17:42295618:G:GT	acceptor_gain	1.0000
17:42295618:GT:G	acceptor_gain	1.0000
17:42295618:GTGC:G	acceptor_gain	1.0000
17:42295618:GTGCA:G	acceptor_gain	1.0000
17:42295792:AGG:A	donor_loss	1.0000
17:42295794:G:GG	donor_gain	1.0000
17:42295794:GT:G	donor_loss	1.0000
17:42295795:T:G	donor_loss	1.0000
17:42299749:A:AG	acceptor_gain	1.0000
17:42299750:G:GT	acceptor_gain	1.0000
17:42299750:GC:G	acceptor_gain	1.0000
17:42299750:GCT:G	acceptor_gain	1.0000
17:42299750:GCTC:G	acceptor_gain	1.0000
17:42299750:GCTCA:G	acceptor_gain	1.0000
17:42299877:GCGTG:G	donor_gain	1.0000
17:42299879:GTG:G	donor_gain	1.0000
17:42299880:TG:T	donor_gain	1.0000
17:42299881:GG:G	donor_gain	1.0000
17:42299882:G:A	donor_loss	1.0000
17:42299882:G:GG	donor_gain	1.0000
17:42300126:TCA:T	acceptor_loss	1.0000

AlphaMissense

5244 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:42295737:T:C	L165P	1.000
17:42299865:T:C	L222P	1.000
17:42300203:T:C	L252P	1.000
17:42300211:T:A	W255R	1.000
17:42300211:T:C	W255R	1.000
17:42300213:G:C	W255C	1.000
17:42300213:G:T	W255C	1.000
17:42300729:C:A	A283D	1.000
17:42300750:G:C	R290P	1.000
17:42300861:T:C	L327P	1.000
17:42300864:T:A	V328E	1.000
17:42301280:T:C	F332S	1.000
17:42301307:T:A	V341D	1.000
17:42301310:T:C	L342P	1.000
17:42301312:A:G	K343E	1.000
17:42301314:G:C	K343N	1.000
17:42301314:G:T	K343N	1.000
17:42301324:A:G	K347E	1.000
17:42301327:T:C	F348L	1.000
17:42301328:T:C	F348S	1.000
17:42301329:T:A	F348L	1.000
17:42301329:T:G	F348L	1.000
17:42301343:G:C	R353P	1.000
17:42301346:T:C	L354P	1.000
17:42301355:G:A	G357D	1.000
17:42301364:T:C	L360P	1.000
17:42301391:T:A	V369E	1.000
17:42301397:C:A	A371D	1.000
17:42301403:T:A	I373N	1.000
17:42304359:T:C	I396T	1.000

dbSNP variants (sampled 300 via entrez): RS1000424638 (17:42289094 T>C), RS1000432381 (17:42294425 G>T), RS1000662517 (17:42298751 T>G), RS1000727263 (17:42299557 G>T), RS1000753273 (17:42288754 G>A,C,T), RS1000818631 (17:42293519 T>G), RS1000880696 (17:42293611 A>G), RS1000911923 (17:42293987 G>C), RS1000949840 (17:42298572 C>A,T), RS1001027356 (17:42298448 A>C,G), RS1001103077 (17:42303682 C>G), RS1001123103 (17:42303823 T>A), RS1001207078 (17:42300481 G>A,C,T), RS1001381509 (17:42309596 C>A,T), RS1001495176 (17:42296182 C>G,T)

Disease associations

OMIM: gene MIM:601511 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): esophageal atresia (MONDO:0001044), pyloric stenosis (MONDO:0001561)

Orphanet (0):

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0002032	Esophageal atresia
HP:0002021	Pyloric stenosis

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST001725_55	Inflammatory bowel disease	6.000000e-22
GCST003602_13	Inflammatory bowel disease	2.000000e-09
GCST004131_42	Inflammatory bowel disease	2.000000e-17
GCST004132_58	Crohn’s disease	2.000000e-11
GCST004133_53	Ulcerative colitis	1.000000e-10
GCST006979_817	Heel bone mineral density	5.000000e-14
GCST007995_3	Asthma (childhood onset)	5.000000e-09
GCST010204_53	Low density lipoprotein cholesterol levels	2.000000e-09
GCST90020025_1438	Waist-to-hip ratio adjusted for BMI	6.000000e-09
GCST90020027_460	Waist-hip index	3.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0009270	heel bone mineral density
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0007788	BMI-adjusted waist-hip ratio

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D004933	Esophageal Atresia	C06.198.330; C06.405.117.260; C16.131.314.330
D017219	Gastric Outlet Obstruction	C06.405.748.340
D011707	Pyloric Stenosis	C06.405.748.340.690

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL4523625 (PROTEIN FAMILY), CHEMBL4523695 (PROTEIN-PROTEIN INTERACTION), CHEMBL5403 (SINGLE PROTEIN), CHEMBL6196141 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

4 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 7,800 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1078178	MOMELOTINIB	4	3,481
CHEMBL413376	SURAMIN HEXASODIUM	3	2,743
CHEMBL603469	LESTAURTINIB	3
CHEMBL1231124	AZD-1480	2	1,576

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — STAT transcription factors

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
AK-2292	Binding	6.68	pKi
compound (±)-2 [PMID: 41108282]	Inhibition	6.14	pKd

Binding affinities (BindingDB)

4 measured of 4 human assays (4 total across all organisms); most potent 4 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
4-(Nonanamidomethyl)-1,2-phenylene bis(dihydrogen phosphate) (6b)	IC50	24900 nM
4-((8-Methylnonanamido)methyl)-1,2-phenylene bis(dihydrogen phosphate) (6a)	IC50	26400 nM
2-Methoxy-4-(nonanamidomethyl)phenyl dihydrogen phosphate (3b)	IC50	98000 nM
2-Methoxy-4-((8-methylnonanamido)methyl)phenyl dihydrogen phosphate (3a)	IC50	152000 nM

ChEMBL bioactivities

59 potent at pChembl≥5 of 64 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.37	Kd	4.225	nM	CHEMBL5653589
8.35	ED50	4.463	nM	CHEMBL5653589
8.30	IC50	5	nM	CHEMBL574058
8.00	IC50	10	nM	LESTAURTINIB
7.60	IC50	25	nM	AZD-1480
7.40	EC50	40	nM	CHEMBL5397297
7.39	IC50	41	nM	CHEMBL5954872
7.39	IC50	41	nM	AZD-1480
7.24	IC50	57	nM	CHEMBL5856025
6.70	IC50	200	nM	CHEMBL5783803
6.40	IC50	400	nM	MOMELOTINIB
6.33	Kd	464	nM	CHEMBL3108909
6.18	Ki	660	nM	CHEMBL6150217
6.17	Ki	680	nM	CHEMBL6146875
6.16	IC50	689	nM	CHEMBL559787
6.02	Ki	960	nM	CHEMBL6169593
6.00	Ki	1000	nM	CHEMBL5403493
6.00	Ki	1000	nM	CHEMBL5395896
6.00	Ki	1000	nM	CHEMBL5395962
6.00	Ki	1000	nM	CHEMBL6169609
6.00	Ki	1000	nM	CHEMBL6148327
5.92	Ki	1200	nM	CHEMBL5402407
5.92	Ki	1200	nM	CHEMBL5416509
5.92	Ki	1200	nM	CHEMBL5428281
5.89	Ki	1300	nM	CHEMBL6132917
5.85	IC50	1400	nM	CHEMBL1253351
5.85	Ki	1400	nM	CHEMBL5398037
5.85	Ki	1400	nM	CHEMBL6173206
5.85	Ki	1400	nM	CHEMBL6170089
5.82	Ki	1500	nM	CHEMBL5430356
5.75	Ki	1800	nM	CHEMBL5438554
5.75	Ki	1800	nM	CHEMBL6161430
5.64	Ki	2300	nM	CHEMBL5419146
5.54	Ki	2900	nM	CHEMBL5398612
5.54	Ki	2900	nM	CHEMBL5395196
5.52	Ki	3000	nM	CHEMBL5422500
5.51	Ki	3100	nM	CHEMBL5396273
5.50	Ki	3200	nM	CHEMBL5419471
5.47	Ki	3400	nM	CHEMBL5408170
5.43	Ki	3700	nM	CHEMBL6152739
5.31	Ki	4900	nM	CHEMBL5416775
5.30	IC50	4970	nM	CHEMBL4088092
5.19	Ki	6400	nM	CHEMBL5406687
5.14	IC50	7200	nM	CHEMBL4104462
5.14	IC50	7300	nM	CHEMBL4104019
5.14	Ki	7300	nM	CHEMBL5425470
5.14	Ki	7300	nM	CHEMBL5440914
5.13	IC50	7400	nM	CHEMBL4077592
5.12	IC50	7600	nM	CHEMBL4085646
5.08	IC50	8400	nM	CHEMBL4103576

PubChem BioAssay actives

44 with measured affinity, of 381 total; 42 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149504: Binding affinity to human STAT5A/STAT5B incubated for 45 mins by Kinobead based pull down assay	kd	0.0042	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	1993937: Inhibition of STAT5 phosphorylation in HEL 92.1.7 cells incubated for 24 hrs by Western blot analysis	ic50	0.0100	uM
5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine	553166: Inhibition of Stat5 phosphorylation in human SET2 cells after 1 hr by Western blotting	ic50	0.0250	uM
N-methyl-4-[[(2S,4S)-2-methyl-1-[[4-(trifluoromethyl)phenyl]methyl]piperidin-4-yl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide	2023980: Inhibition of STAT5 phosphorylation in human SK-MES-1 cells pretreated for 30 mins followed by GM-CSF stimulation by Western blot analysis	ec50	0.0400	uM
Momelotinib	2184226: Inhibition of STAT5 phosphorylation in human HEL cells by Western blot analysis	ic50	0.4000	uM
4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]benzoic acid	1064896: Binding affinity to His-tagged STAT5 (unknown origin) by SPR spectroscopic analysis	kd	0.4640	uM
(16R,17S)-16,17-dihydroxy-4,14,19-triazaheptacyclo[12.11.2.02,6.07,27.08,13.019,26.020,25]heptacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	426944: Inhibition of STAT5 phosphorylation in IL2-stimulated healthy human T cells by Western blotting	ic50	0.6890	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	1.0000	uM
[[2-[[(2S)-1-[(2S)-2-[1,3-benzothiazol-5-yl-[3-[5-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]pent-4-ynylamino]-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	1.0000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-3-(4-fluorophenyl)-1-oxopropan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	1.0000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-naphthalen-2-ylcarbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	1.2000	uM
[[2-[[(2S)-1-[(2S)-2-[1-benzothiophen-5-yl-[3-[5-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-4-yl]pent-4-ynylamino]-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	1.2000	uM
[[2-[[(2S)-3-(4-bromophenyl)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	1.2000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	1.4000	uM
octasodium;4-[[3-[[3,5-bis[(2,4-disulfonatophenyl)carbamoyl]phenyl]carbamoylamino]-5-[(2,4-disulfonatophenyl)carbamoyl]benzoyl]amino]benzene-1,3-disulfonate	1486488: Inhibition of 5-carboxyfluorescein-GpYLVLDKW-OH binding to C-terminal 6x-His-tagged and an N-terminal maltose-binding protein-tagged STAT5A SH2 domain (137 to 507 residues) (unknown origin) expressed in Escherichia coli Rosetta BL21 DE3 pre-incubated for 1 hr before fluorescent-labelled peptide addition by fluorescence polarization assay	ic50	1.4000	uM
[[2-[[(2S)-1-[(2S)-2-[(4-bromophenyl)-[3-(dimethylamino)-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	1.5000	uM
[[2-[[(2S)-1-[(2S)-2-[1,3-benzothiazol-5-yl-[3-(dimethylamino)-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	1.8000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-[4-(trifluoromethyl)phenyl]propan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	2.3000	uM
[[2-[[(2S)-1-[(2S)-2-[(4-chlorophenyl)-[3-(dimethylamino)-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	2.9000	uM
[[2-[[(1S)-1-cyclopropyl-2-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	2.9000	uM
[[2-[[(2S)-1-[(2S)-2-(3,4-dihydro-2H-quinoline-1-carbonyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	3.0000	uM
[[2-[[(2S)-1-[(2S)-2-[1-benzofuran-5-yl-[3-(dimethylamino)-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	3.1000	uM
[[2-[[(1S)-2-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[4-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	3.2000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-(4-phenylphenyl)carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	3.4000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-[3-(1,3-thiazol-2-yl)phenyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	4.9000	uM
[4-[[[2-[6-(phenylcarbamoyl)naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485963: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from C-terminal His6-tagged/N-terminal maltose-binding protein-tagged STAT5A SH2 domain (unknown origin) (137 to 707 residues) Escherichia coli BL21(DE3) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	4.9700	uM
[[2-[[(2S)-3,3-dimethyl-1-[(2S)-2-[methyl(phenyl)carbamoyl]pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	6.4000	uM
[4-[[[2-[6-[(4-fluorophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485960: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5A SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	7.2000	uM
[4-[[[2-[6-[(3-chlorophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485960: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5A SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	7.3000	uM
[[2-[[(2S)-1-[(2S)-2-(3,4-dihydro-1H-isoquinoline-2-carbonyl)pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	7.3000	uM
[[2-[[(2S)-1-[(2S)-2-[(3-bromophenyl)-[3-(dimethylamino)-3-oxopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	7.3000	uM
[4-[[[2-[4-[(4-chlorophenyl)carbamoyl]phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485960: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5A SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	7.4000	uM
[4-[[[2-[6-[(4-bromophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485960: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5A SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	7.6000	uM
[4-[[[2-[4-[(4-fluorophenyl)carbamoyl]phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485960: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5A SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	8.3000	uM
[4-[[[2-[6-[(3-fluorophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485960: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5A SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	8.4000	uM
[4-[[[2-[4-[(4-bromophenyl)carbamoyl]phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485960: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5A SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	8.6000	uM
hexasodium;8-[[3-[[3-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]phenyl]carbamoylamino]benzoyl]amino]naphthalene-1,3,5-trisulfonate;hydrate	1486488: Inhibition of 5-carboxyfluorescein-GpYLVLDKW-OH binding to C-terminal 6x-His-tagged and an N-terminal maltose-binding protein-tagged STAT5A SH2 domain (137 to 507 residues) (unknown origin) expressed in Escherichia coli Rosetta BL21 DE3 pre-incubated for 1 hr before fluorescent-labelled peptide addition by fluorescence polarization assay	ic50	8.8000	uM
[4-[[[2-[6-[(4-chlorophenyl)carbamoyl]naphthalen-2-yl]oxyacetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485960: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5A SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	8.9000	uM
[4-[[[2-[4-[(3-chlorophenyl)carbamoyl]phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485960: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5A SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	9.1000	uM
hexasodium;8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonate	1486488: Inhibition of 5-carboxyfluorescein-GpYLVLDKW-OH binding to C-terminal 6x-His-tagged and an N-terminal maltose-binding protein-tagged STAT5A SH2 domain (137 to 507 residues) (unknown origin) expressed in Escherichia coli Rosetta BL21 DE3 pre-incubated for 1 hr before fluorescent-labelled peptide addition by fluorescence polarization assay	ic50	9.4000	uM
[4-[[[2-[4-(phenylcarbamoyl)phenoxy]acetyl]amino]methyl]-2-phosphonooxyphenyl] dihydrogen phosphate	1485960: Displacement of 5-carboxyfluorescein-GY(PO3H2)LVLDKW from STAT5A SH2 domain (unknown origin) pretreated for 1 hr followed by fluorescent tracer addition after 1 hr by fluorescence polarization assay	ic50	9.7000	uM
[[2-[[(2S)-1-[(2S)-2-[[3-(dimethylamino)-3-oxopropyl]-phenylcarbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamoyl]-1-benzothiophen-5-yl]-difluoromethyl]phosphonic acid	2027878: Binding affinity to N-terminal 6his-tagged human STAT5A (136 to 705 residues) expressed in Escherichia coli BL21-DE3 rosetta cells assessed as inhibition constant by FP assay	ki	10.0000	uM

CTD chemical–gene interactions

77 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects splicing, decreases expression, increases abundance, increases expression	5
Valproic Acid	decreases expression, increases methylation, affects expression	4
tofacitinib	decreases phosphorylation, decreases reaction, increases phosphorylation	3
(+)-JQ1 compound	affects localization, increases phosphorylation, decreases phosphorylation, decreases expression, affects binding (+2 more)	3
Sorafenib	decreases activity, decreases phosphorylation, increases reaction	3
Arsenic Trioxide	decreases expression, decreases activity, decreases phosphorylation, increases expression	3
Dronabinol	decreases reaction, increases phosphorylation, increases reaction, affects reaction, increases expression	3
ponatinib	decreases phosphorylation, increases reaction	2
Arsenic	increases abundance, increases expression	2
Vehicle Emissions	affects cotreatment, increases expression, decreases expression, increases abundance	2
Lipopolysaccharides	increases phosphorylation, affects binding, decreases reaction, affects localization, affects reaction (+3 more)	2
Nickel	increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Progesterone	affects localization, increases phosphorylation, increases reaction, increases expression	2
Silicon Dioxide	increases expression	2
Testosterone	affects cotreatment, increases expression, increases activity	2
Particulate Matter	decreases methylation, increases abundance, increases expression, decreases expression	2
alpinumisoflavone	decreases phosphorylation, decreases activity	1
aristolochic acid I	increases expression	1
2-hydroxy-1-(2-((9-(4-methylcyclohexyl)-9H-pyrido(4’,3’-4,5)pyrrolo(2,3-d)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone	decreases phosphorylation	1
GSK-J4	increases expression	1
mivebresib	decreases expression	1
TL8-506	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
diphenyleneiodonium	decreases reaction, increases phosphorylation	1
benzo(a)pyrene-3,6-quinone	affects localization, increases phosphorylation	1
cobaltous chloride	decreases expression	1
nickel sulfate	increases expression	1
benzo(a)pyrene-1,6-quinone	affects localization, increases phosphorylation	1

ChEMBL screening assays

199 unique, capped per target: 199 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4362110	Binding	Effect on STAT5a/b at Y694/Y699 phosphorylation level in human NCI-H1975 incubated for 12 hrs by human phosphokinase proteome profiler array relative to control	Structure-guided development of purine amide, hydroxamate, and amidoxime for the inhibition of non-small cell lung cancer. — Eur J Med Chem

Cellosaurus cell lines

12 cell lines: 7 cancer cell line, 3 embryonic stem cell, 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A6U8	SEES3-1V human STAT5A, clone1	Embryonic stem cell	Male
CVCL_A6U9	SEES3-1V human STAT5A, clone2	Embryonic stem cell	Male
CVCL_A6V0	SEES3-1V human STAT5A, clone3	Embryonic stem cell	Male
CVCL_B7ZN	Abcam Raji STAT5A KO	Cancer cell line	Male
CVCL_C0AG	Abcam THP-1 STAT5A KO	Cancer cell line	Male
CVCL_C7C4	Abcam PC-3 STAT5A KO	Cancer cell line	Male
CVCL_D8BM	Ubigene A-549 STAT5A KO	Cancer cell line	Male
CVCL_E0Q5	Ubigene HeLa STAT5A KO	Cancer cell line	Female
CVCL_E8ED	HEK-Blue CD122/CD132	Transformed cell line	Female
CVCL_UF26	HEK-Blue IL-2	Transformed cell line	Female

Clinical trials (associated diseases)

59 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00556283	PHASE4	COMPLETED	RCT: STARR vs Biofeedback
NCT00226044	PHASE3	COMPLETED	Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
NCT03127345	PHASE2	WITHDRAWN	Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health
NCT02033772	Not specified	COMPLETED	Prospective Data Collection of Patients < 6 Months of Age Undergoing Thoracoscopic Surgery
NCT02466451	Not specified	COMPLETED	Study in Children With the Diagnosis of Congenital Diaphragmatic Hernia (CDH) and Oesophageal Atresia (EA)
NCT02525705	Not specified	COMPLETED	Dumping Syndrome After Operation of Esophageal Atresia Type III
NCT02883725	Not specified	COMPLETED	National Register of Oesophageal Atresia
NCT03023865	Not specified	UNKNOWN	Individualized Management for Long Gap Esophageal Atresia
NCT03415893	Not specified	COMPLETED	High-resolution Esophageal Manometry
NCT03455881	Not specified	UNKNOWN	Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients
NCT03615495	Not specified	COMPLETED	Flourish™ Pediatric Esophageal Atresia
NCT03619408	Not specified	UNKNOWN	Management of Esophagitis Following Repair of Esophageal Atresia
NCT03666767	Not specified	COMPLETED	Management and Outcomes of Congenital Anomalies in Low-, Middle- and High-Income Countries
NCT03730454	Not specified	ACTIVE_NOT_RECRUITING	Transanastomotic Tube for Proximal Esophageal Atresia With Distal Tracheoesophageal Fistula Repair
NCT03767673	Not specified	UNKNOWN	Cardiorespiratory Performance and Pulmonary Microbiome in Patients After Repair of Esophageal Atresia
NCT03999008	Not specified	UNKNOWN	Oral Viscous Budesonide in Anastomotic Stricture After Esophageal Atresia Repair (OVB in EA)
NCT04072419	Not specified	UNKNOWN	Application of Enhanced Recovery After Surgery for Congenital Esophageal Atresia During Perioperative Period
NCT04136795	Not specified	UNKNOWN	Evaluation of the Respiratory Impact After Conventional or Minimally Invasive Esophageal Atresia Surgery
NCT04259528	Not specified	UNKNOWN	Endoscopic Ultrasound Findings in Esophageal Atresia Following Surgical Repair
NCT04522193	Not specified	RECRUITING	Dumping Syndrome and Esophageal Atresia
NCT04901546	Not specified	COMPLETED	Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome
NCT04932746	Not specified	COMPLETED	The Effect of Dexmedetomidine on Oxygen During One Lung Ventilation in Pediatric Surgery.
NCT05129930	Not specified	COMPLETED	Fluid Overload and Pulmonary Function
NCT05527873	Not specified	COMPLETED	Respiratory Complications of Operated Esophageal Atresia in Children
NCT05995171	Not specified	RECRUITING	Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence
NCT06073158	Not specified	COMPLETED	Molecular Signatures of Esophageal Atresia
NCT06208449	Not specified	UNKNOWN	Robotic Versus Thoracoscopy Versus Thoracotomy Repair for Congenital Esophageal Atresia
NCT06335862	Not specified	ENROLLING_BY_INVITATION	Primary Posterior Tracheopexy Prevents Tracheal Collapse
NCT06731855	Not specified	RECRUITING	An Exploratory Physiological Study of Post-operative Recovery in Surgical Neonates and Dimethylarginine:Arginine Levels
NCT06860919	Not specified	RECRUITING	Prospective Evaluation of the Results of Multidisciplinary Follow-up After a Transitional Consultation for Esophageal Atresia
NCT06975982	Not specified	RECRUITING	Symptoms, Pulmonary Function, Muscle Strength, Exercise Capacity, and Frailty in Esophageal Atresia vs. Healthy Peers
NCT07100379	Not specified	RECRUITING	Balloon Inflation Time for Esophageal Strictures (BITES): A Randomized Multi-Center Study
NCT07210736	Not specified	NOT_YET_RECRUITING	Brazilian Multicenter Study on Esophageal Atresia
NCT03223480	PHASE2/PHASE3	COMPLETED	EUS - Guided Balloon-occluded Gastrojejunostomy Bypass
NCT01139853	EARLY_PHASE1	COMPLETED	Post-Operative Impact of Nasogastric Tubes on Rates of Emesis in Infants Diagnosed With Pyloric Stenosis
NCT00144924	Not specified	TERMINATED	Open vs Laparoscopic Pyloromyotomy for Pyloric Stenosis
NCT00409734	Not specified	COMPLETED	Frequency of Formula Change Prior to the Accurate Diagnosis of Pyloric Stenosis
NCT00487552	Not specified	TERMINATED	Magnetic Anastomosis Device Relief of Malignant Gastric Outlet Obstruction
NCT00991614	Not specified	COMPLETED	EVOLUTION® Duodenal Stent for Duodenal or Gastric Outlet Obstruction Caused by Malignant Neoplasms
NCT01839292	Not specified	COMPLETED	ComVi and D-type Stent in Malignant GOO